A panel decided Friday to send dozens of lawsuits filed over Ozempic and related drugs prescribed for type 2 diabetes, but increasingly used for weight loss, to a federal judge in Philadelphia.

The U.S. Judicial Panel on Multidistrict Litigation rejected arguments from defendants Novo Nordisk and Eli Lilly to send the cases to other venues, such as North Carolina or California. The panel concluded that at least 13 of the 55 lawsuits so far are in the Eastern District of Pennsylvania.